OIG: FDA’s EUA Approach Allowed Bad Tests To Reach Market
Executive Summary
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.
You may also be interested in...
FDA Updates COVID-19 Test Policy; Shifts Focus From EUAs
As part of a policy revamp, FDA encourages COVID-19 test developers to pursue traditional premarket review pathways rather than emergency use authorizations.
FDA Updates COVID-19 Test Policy; Shifts Focus From EUAs
As part of a policy revamp, the US FDA is encouraging COVID-19 test developers to pursue traditional premarket review pathways rather than emergency use authorizations.
FDA Releases COVID-19 Test Performance Data
The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.